Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature

Shihui Liu, Hailun Wang, Brooke M. Currie, Alfredo Molinolo, Howard J. Leung, Mahtab Moayeri, John R. Basile, Randall W. Alfano, J. Silvio Gutkind, Arthur E. Frankel, Thomas H. Bugge, Stephen H. Leppla

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Anthrax lethal toxin (LT), a virulence factor secreted by Bacillus anthracis, is selectively toxic to human melanomas with the BRAF V600E activating mutation because of its proteolytic activities toward the mitogen-activated protein kinase kinases (MEKs). To develop LT variants with lower in vivo toxicity and high tumor specificity, and therefore greater potential for clinical use, we generated a mutated LT that requires activation by matrix metalloproteinases (MMPs). This engineered toxin was less toxic than wild-type LT to mice because of the limited expression of MMPs by normal cells. Moreover, the systemically administered toxin produced greater anti-tumor effects than wild-type LT toward human xenografted tumors. This was shown to result from its greater bioavailability, a consequence of the limited uptake and clearance of the modified toxin by normal cells. Furthermore, the MMP-activated LT had very potent anti-tumor activity not only to human melanomas containing the BRAF mutation but also to other tumor types, including lung and colon carcinomas regardless of their BRAF status. Tumor histology and in vivo angiogenesis assays showed that this antitumor activity is due largely to the indirect targeting of tumor vasculature and angiogenic processes. Thus, even tumors genetically deficient in anthrax toxin receptors were still susceptible to the toxin therapy in vivo. Moreover, the modified toxin also displayed lower immunogenicity compared with the wild-type toxin. All these properties suggest that this MMP-activated antitumor toxin has potential for use in cancer therapy.

Original languageEnglish (US)
Pages (from-to)529-540
Number of pages12
JournalJournal of Biological Chemistry
Volume283
Issue number1
DOIs
StatePublished - Jan 4 2008

Fingerprint

Matrix Metalloproteinases
Tumors
Neoplasms
Poisons
Melanoma
Histology
anthrax toxin
Bacillus anthracis
Mitogen-Activated Protein Kinase Kinases
Mutation
Virulence Factors
Bacilli
Toxicity
Assays
Biological Availability
Chemical activation
Colon
Carcinoma
Lung
Therapeutics

ASJC Scopus subject areas

  • Biochemistry

Cite this

Liu, S., Wang, H., Currie, B. M., Molinolo, A., Leung, H. J., Moayeri, M., ... Leppla, S. H. (2008). Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. Journal of Biological Chemistry, 283(1), 529-540. https://doi.org/10.1074/jbc.M707419200

Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. / Liu, Shihui; Wang, Hailun; Currie, Brooke M.; Molinolo, Alfredo; Leung, Howard J.; Moayeri, Mahtab; Basile, John R.; Alfano, Randall W.; Gutkind, J. Silvio; Frankel, Arthur E.; Bugge, Thomas H.; Leppla, Stephen H.

In: Journal of Biological Chemistry, Vol. 283, No. 1, 04.01.2008, p. 529-540.

Research output: Contribution to journalArticle

Liu, S, Wang, H, Currie, BM, Molinolo, A, Leung, HJ, Moayeri, M, Basile, JR, Alfano, RW, Gutkind, JS, Frankel, AE, Bugge, TH & Leppla, SH 2008, 'Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature', Journal of Biological Chemistry, vol. 283, no. 1, pp. 529-540. https://doi.org/10.1074/jbc.M707419200
Liu, Shihui ; Wang, Hailun ; Currie, Brooke M. ; Molinolo, Alfredo ; Leung, Howard J. ; Moayeri, Mahtab ; Basile, John R. ; Alfano, Randall W. ; Gutkind, J. Silvio ; Frankel, Arthur E. ; Bugge, Thomas H. ; Leppla, Stephen H. / Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 1. pp. 529-540.
@article{afe74055d3e3435db0f384695218fc67,
title = "Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature",
abstract = "Anthrax lethal toxin (LT), a virulence factor secreted by Bacillus anthracis, is selectively toxic to human melanomas with the BRAF V600E activating mutation because of its proteolytic activities toward the mitogen-activated protein kinase kinases (MEKs). To develop LT variants with lower in vivo toxicity and high tumor specificity, and therefore greater potential for clinical use, we generated a mutated LT that requires activation by matrix metalloproteinases (MMPs). This engineered toxin was less toxic than wild-type LT to mice because of the limited expression of MMPs by normal cells. Moreover, the systemically administered toxin produced greater anti-tumor effects than wild-type LT toward human xenografted tumors. This was shown to result from its greater bioavailability, a consequence of the limited uptake and clearance of the modified toxin by normal cells. Furthermore, the MMP-activated LT had very potent anti-tumor activity not only to human melanomas containing the BRAF mutation but also to other tumor types, including lung and colon carcinomas regardless of their BRAF status. Tumor histology and in vivo angiogenesis assays showed that this antitumor activity is due largely to the indirect targeting of tumor vasculature and angiogenic processes. Thus, even tumors genetically deficient in anthrax toxin receptors were still susceptible to the toxin therapy in vivo. Moreover, the modified toxin also displayed lower immunogenicity compared with the wild-type toxin. All these properties suggest that this MMP-activated antitumor toxin has potential for use in cancer therapy.",
author = "Shihui Liu and Hailun Wang and Currie, {Brooke M.} and Alfredo Molinolo and Leung, {Howard J.} and Mahtab Moayeri and Basile, {John R.} and Alfano, {Randall W.} and Gutkind, {J. Silvio} and Frankel, {Arthur E.} and Bugge, {Thomas H.} and Leppla, {Stephen H.}",
year = "2008",
month = "1",
day = "4",
doi = "10.1074/jbc.M707419200",
language = "English (US)",
volume = "283",
pages = "529--540",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

TY - JOUR

T1 - Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature

AU - Liu, Shihui

AU - Wang, Hailun

AU - Currie, Brooke M.

AU - Molinolo, Alfredo

AU - Leung, Howard J.

AU - Moayeri, Mahtab

AU - Basile, John R.

AU - Alfano, Randall W.

AU - Gutkind, J. Silvio

AU - Frankel, Arthur E.

AU - Bugge, Thomas H.

AU - Leppla, Stephen H.

PY - 2008/1/4

Y1 - 2008/1/4

N2 - Anthrax lethal toxin (LT), a virulence factor secreted by Bacillus anthracis, is selectively toxic to human melanomas with the BRAF V600E activating mutation because of its proteolytic activities toward the mitogen-activated protein kinase kinases (MEKs). To develop LT variants with lower in vivo toxicity and high tumor specificity, and therefore greater potential for clinical use, we generated a mutated LT that requires activation by matrix metalloproteinases (MMPs). This engineered toxin was less toxic than wild-type LT to mice because of the limited expression of MMPs by normal cells. Moreover, the systemically administered toxin produced greater anti-tumor effects than wild-type LT toward human xenografted tumors. This was shown to result from its greater bioavailability, a consequence of the limited uptake and clearance of the modified toxin by normal cells. Furthermore, the MMP-activated LT had very potent anti-tumor activity not only to human melanomas containing the BRAF mutation but also to other tumor types, including lung and colon carcinomas regardless of their BRAF status. Tumor histology and in vivo angiogenesis assays showed that this antitumor activity is due largely to the indirect targeting of tumor vasculature and angiogenic processes. Thus, even tumors genetically deficient in anthrax toxin receptors were still susceptible to the toxin therapy in vivo. Moreover, the modified toxin also displayed lower immunogenicity compared with the wild-type toxin. All these properties suggest that this MMP-activated antitumor toxin has potential for use in cancer therapy.

AB - Anthrax lethal toxin (LT), a virulence factor secreted by Bacillus anthracis, is selectively toxic to human melanomas with the BRAF V600E activating mutation because of its proteolytic activities toward the mitogen-activated protein kinase kinases (MEKs). To develop LT variants with lower in vivo toxicity and high tumor specificity, and therefore greater potential for clinical use, we generated a mutated LT that requires activation by matrix metalloproteinases (MMPs). This engineered toxin was less toxic than wild-type LT to mice because of the limited expression of MMPs by normal cells. Moreover, the systemically administered toxin produced greater anti-tumor effects than wild-type LT toward human xenografted tumors. This was shown to result from its greater bioavailability, a consequence of the limited uptake and clearance of the modified toxin by normal cells. Furthermore, the MMP-activated LT had very potent anti-tumor activity not only to human melanomas containing the BRAF mutation but also to other tumor types, including lung and colon carcinomas regardless of their BRAF status. Tumor histology and in vivo angiogenesis assays showed that this antitumor activity is due largely to the indirect targeting of tumor vasculature and angiogenic processes. Thus, even tumors genetically deficient in anthrax toxin receptors were still susceptible to the toxin therapy in vivo. Moreover, the modified toxin also displayed lower immunogenicity compared with the wild-type toxin. All these properties suggest that this MMP-activated antitumor toxin has potential for use in cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=38049098266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049098266&partnerID=8YFLogxK

U2 - 10.1074/jbc.M707419200

DO - 10.1074/jbc.M707419200

M3 - Article

VL - 283

SP - 529

EP - 540

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 1

ER -